{
    "pmid": "41463084",
    "title": "Liquid Biopsy and Multi-Omic Biomarkers in Breast Cancer: Innovations in Early Detection, Therapy Guidance, and Disease Monitoring.",
    "abstract": "Liquid biopsy and multi-omic biomarker integration are transforming precision oncology in breast cancer, providing real-time, minimally invasive insights into tumor biology. By analyzing circulating tumor DNA, circulating tumor cells, exosomal non-coding RNAs, and proteomic or metabolomic profiles, clinicians can monitor clonal evolution, therapeutic response, and recurrence risk in real time. Recent advances in sequencing technologies, methylation profiling, and artificial intelligence-driven data integration have markedly improved diagnostic sensitivity and predictive accuracy. Multi-omic frameworks combining genomic, transcriptomic, and proteomic data enable early detection of resistance, molecular stratification, and identification of actionable targets, while machine learning models enhance outcome prediction and therapy optimization. Despite these advances, key challenges persist. Pre-analytical variability, lack of standardized protocols, and disparities in access continue to limit reproducibility and clinical adoption. High costs, incomplete regulatory validation, and the absence of definitive evidence for mortality reduction underscore the need for larger, prospective trials. Integrating multi-omic assays into clinical workflows will require robust bioinformatics pipelines, clinician-friendly reporting systems, and interdisciplinary collaboration among molecular scientists, data engineers, and oncologists. In the near future, liquid biopsy is expected to complement, not replace, traditional tissue analysis, serving as a cornerstone of adaptive cancer management. As sequencing becomes faster and more affordable, multi-omic and AI-driven analyses will allow earlier detection, more precise treatment adjustments, and continuous monitoring across the disease course. Ultimately, these innovations herald a shift toward real-time, data-driven oncology that personalizes breast cancer care and improves patient outcomes.",
    "disease": "breast cancer",
    "clean_text": "liquid biopsy and multi omic biomarkers in breast cancer innovations in early detection therapy guidance and disease monitoring liquid biopsy and multi omic biomarker integration are transforming precision oncology in breast cancer providing real time minimally invasive insights into tumor biology by analyzing circulating tumor dna circulating tumor cells exosomal non coding rnas and proteomic or metabolomic profiles clinicians can monitor clonal evolution therapeutic response and recurrence risk in real time recent advances in sequencing technologies methylation profiling and artificial intelligence driven data integration have markedly improved diagnostic sensitivity and predictive accuracy multi omic frameworks combining genomic transcriptomic and proteomic data enable early detection of resistance molecular stratification and identification of actionable targets while machine learning models enhance outcome prediction and therapy optimization despite these advances key challenges persist pre analytical variability lack of standardized protocols and disparities in access continue to limit reproducibility and clinical adoption high costs incomplete regulatory validation and the absence of definitive evidence for mortality reduction underscore the need for larger prospective trials integrating multi omic assays into clinical workflows will require robust bioinformatics pipelines clinician friendly reporting systems and interdisciplinary collaboration among molecular scientists data engineers and oncologists in the near future liquid biopsy is expected to complement not replace traditional tissue analysis serving as a cornerstone of adaptive cancer management as sequencing becomes faster and more affordable multi omic and ai driven analyses will allow earlier detection more precise treatment adjustments and continuous monitoring across the disease course ultimately these innovations herald a shift toward real time data driven oncology that personalizes breast cancer care and improves patient outcomes"
}